As miR483-3p may downregulate ACE2 and AT2R levels, miR-483-3p would not be a therapeutic target for cardiovascular diseases due to the opposing functions of AGT/ACE1 versus ACE2/AT2R. This evidence concerns the gene ACE2 and cardiovascular disorder.